CDP870, a pegylated humanized anti-TNF antibody fragment, offers particular benefit to Crohn's disease patients with elevated C-reactive protein

Schreiber, Stefan; Rutgeerts, Paul; Innes, Alison; Patel, Jatin
September 2003
American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS245
Academic Journal
An abstract of the article concerning the benefit of CDP870 on Crohn's disease patients with elevated C-reactive protein is presented.


Related Articles

  • Natalizumab for Active Crohn's Disease. Ghosh, Subrata; Goldin, Eran; Gordon, Fiona H.; Malchow, Helmut A.; Rask-Madsen, Jørgen; Rutgeerts, Paul; Vyhnálek, Petr; Zádorová, Zdena; Palmer, Tanya; Donoghue, Stephen // New England Journal of Medicine;1/2/2003, Vol. 348 Issue 1, p24 

    Background: In chronic inflammatory conditions such as Crohn's disease, the migration of leukocytes from the circulation into the parenchyma and their activation within inflammatory sites are mediated in part by α4 integrins. Methods: We conducted a double-blind, placebo-controlled trial of...

  • Mesenteric fat in Crohn's disease: the hot spot of inflammation? Siegmund, Britta // Gut;Jan2012, Vol. 61 Issue 1, p3 

    The article comments on two studies on fat and Crohn's disease including one on the role of mesenteric fat by Peyrin-Biroulet et al and fat tissues in various parts of a patient with CD by Zulian et al. Findings of the Peyrin-Biroulet et al study, it says, demonstrated the equal production of...

  • Influence of Topically and Systemically Active Steroids on Circulating Leukocytes in Crohn's Disease. Tillinger, W.; Gasche, C.; Reinisch, W.; Lichtenberger, C.; Bakos, S.; Dejaco, C.; Moser, G.; Vogelsang, H.; Gangl, A.; Lochs, H. // American Journal of Gastroenterology;Oct1998, Vol. 93 Issue 10, p1848 

    Objective: Budesonide, although only topically active, is effective in the treatment of Crohn's disease. This study was performed to compare the clinical efficacies of budesonide and prednisolone in relation to the activation status of circulating leukocytes. Methods: Twenty-four patients with...

  • C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. Koelewijn, Chantal L.; Schwartz, Matthijs P.; Samsom, Melvin; Oldenburg, Bas // World Journal of Gastroenterology;1/7/2008, Vol. 14 Issue 1, p85 

    AIM: To explore if C-reactive protein (CRP) levels might serve as a prognostic factor with respect to the clinical course of Crohn's disease and might be useful for classification. METHODS: In this retrospective cohort study we enrolled 94 patients from the inflammatory bowel disease (IBD)...

  • Intestinal Permeability Test as a Predictor of Clinical Course in Crohn's Disease. D'Incà, Renata; Di Leo, Vincenza; Corrao, Giovanni; Martines, Diego; D'Odorico, Anna; Mestriner, Cinzia; Venturi, Carla; Longo, Giuseppe; Sturniolo, Giacomo Carlo // American Journal of Gastroenterology;Oct1999, Vol. 94 Issue 10, p2956 

    OBJECTIVE: The clinical course of Crohn's disease is often unpredictable. The aim of this study was to select the most useful parameters able to predict clinical relapses. METHODS: One hundred-thirty Crohn's disease patients in clinical remission were followed every 4 months for 2 yr or until...

  • Erratum to: Platelet Activation Markers Are Associated with Crohn's Disease Activity in Patients with Low C-Reactive Protein. Takeyama, Hiroshi; Mizushima, Tsunekazu; Iijima, Hideki; Shinzaki, Shinichiro; Uemura, Mamoru; Nishimura, Junichi; Hata, Taishi; Takemasa, Ichiro; Yamamoto, Hirofumi; Doki, Yuichiro; Mori, Masaki // Digestive Diseases & Sciences;Dec2015, Vol. 60 Issue 12, p3827 

    No abstract available.

  • Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Balzola, Federico; Bernstein, Charles; Ho, Gwo-Tzer; Russell, Richard K. // Inflammatory Bowel Disease Monitor;2011, Vol. 12 Issue 2, p69 

    The article presents a randomized controlled trial of using fructo-oligosaccharide (FOS) in patients with Crohn's disease. The study shows that there was no clinical benefit seen in patients having moderate Crohn's disease receiving FOS treatment. It reveals that fecal calprotectin and...

  • Efficacy of T2 in Active Crohn’s Disease: A Prospective Study Report. Qingsong Tao; Xinbo Wang; Zhiming Wang; Jieshou Li // Digestive Diseases & Sciences;Aug2007, Vol. 52 Issue 8, p1790 

    Abstract  To date few therapies have been shown to reliably prevent the evolution of Crohn’s disease (CD). The traditional Chinese medicine, Tripterygium wilfordii Hook F (TWHF), has both immunomodulatory and anti-inflammatory activities. Our aim was to investigate...

  • Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Massey, D. C. O.; Bredin, F.; Parkes, M // Gut;Sep2008, Vol. 57 Issue 9, p1294 

    We present the case of a 37-year-old woman with severe refractory colonic and perianal Crohns disease who had lost response to second-line, steroid-sparing treatments azathioprine, methotrexate and infliximab. For many such patients extensive surgery has often been considered the only option....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics